300 related articles for article (PubMed ID: 34111952)
21. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Parrondo RD; Dutta N; LaPlant BR; Elliott J; Fernandez A; Zimmerman A; Cicco G; Han B; Heslop K; Chapin D; Sher T; Roy V; Rasheed A; Das S; Chanan-Khan AA; Paulus A; Ailawadhi S
Br J Haematol; 2024 May; 204(5):1825-1829. PubMed ID: 38286472
[TBL] [Abstract][Full Text] [Related]
22. At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?
Tyczyńska A; Zaucha J
Adv Clin Exp Med; 2024 Apr; 33(4):409-418. PubMed ID: 37589225
[TBL] [Abstract][Full Text] [Related]
23. Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study.
Mian H; Seow H; Pond GR; Gayowsky A; Foley R; Balistky A; Ebraheem M; Cipkar C; Sapru H; Mohyuddin GR; Hadidi SA; Visram A
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e227-e234. PubMed ID: 38431522
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
Kastritis E; Ntanasis-Stathopoulos I; Theodorakakou F; Migkou M; Roussou M; Malandrakis P; Kanellias N; Eleutherakis-Papaiakovou E; Fotiou D; Spiliopoulou V; Gavriatopoulou M; Patel S; Majer I; Boukis C; Fetani A; Dimopoulos MA; Terpos E
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38616479
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain.
Iriuchishima H; Saito A; Mihara M; Terasaki Y; Matsumoto A; Isoda A; Furukawa Y; Matsumoto M
Int J Hematol; 2024 Mar; ():. PubMed ID: 38551778
[TBL] [Abstract][Full Text] [Related]
26. LINC00461 Knockdown Enhances the Effect of Ixazomib in Multiple Myeloma Cells.
Deng M; Yuan H; Peng H; Liu S; Xiao X; Wang Z; Zhang G; Xiao H
Curr Cancer Drug Targets; 2023; 23(8):643-652. PubMed ID: 36927430
[TBL] [Abstract][Full Text] [Related]
27. Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma.
Ramirez KG
J Adv Pract Oncol; 2017; 8(4):401-405. PubMed ID: 30018846
[TBL] [Abstract][Full Text] [Related]
28. Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.
Abdallah N; Witzig TE; Kumar SK; Lacy MQ; Hayman SR; Dispenzieri A; Roy V; Gertz MA; Bergsagel PL; Rajkumar SV
Leukemia; 2024 May; 38(5):1169-1171. PubMed ID: 38418610
[No Abstract] [Full Text] [Related]
29. Maintain maintenance in multiple myeloma?
Zweegman S; van de Donk NWJC
Blood; 2023 Nov; 142(18):1501-1502. PubMed ID: 37917081
[No Abstract] [Full Text] [Related]
30. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Kawaji-Kanayama Y; Kobayashi T; Muramatsu A; Uchiyama H; Sasaki N; Uoshima N; Nakao M; Takahashi R; Shimura K; Kaneko H; Kiyota M; Wada K; Chinen Y; Hirakawa K; Fuchida SI; Shimazaki C; Matsumura-Kimoto Y; Mizutani S; Tsukamoto T; Shimura Y; Horiike S; Taniwaki M; Kuroda J;
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1476. PubMed ID: 34124862
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma.
Zheng Z; Lin K
Am J Transl Res; 2021; 13(5):5248-5255. PubMed ID: 34150115
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.
Moreau P; Ghori R; Farooqui M; Marinello P; San Miguel J
Br J Haematol; 2021 Jul; 194(1):e48-e51. PubMed ID: 34114211
[No Abstract] [Full Text] [Related]
34. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Dispenzieri A; Kastritis E; Wechalekar AD; Schönland SO; Kim K; Sanchorawala V; Landau HJ; Kwok F; Suzuki K; Comenzo RL; Berg D; Liu G; Kumar A; Faller DV; Merlini G
Leukemia; 2022 Jan; 36(1):225-235. PubMed ID: 34168284
[TBL] [Abstract][Full Text] [Related]
35. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
[TBL] [Abstract][Full Text] [Related]
36. Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Vogt C; Fernández RA; Bittrich M; Ruiz-Heredia Y; Da Viá M; Zovko J; Garitano-Trojaola A; Bolli N; Ruckdeschel A; Stühmer T; Chatterjee M; Kull M; Krönke J; Agirre X; Martin-Subero JI; Raab P; Einsele H; Rasche L; Martinez-Lopez J; Haaf T; Kortüm KM
Blood; 2021 Nov; 138(18):1721-1726. PubMed ID: 34115836
[TBL] [Abstract][Full Text] [Related]
37. A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma.
Liu L; Fiala M; Gao F; King J; Goldsmith S; Wildes TM; Stockerl-Goldstein K; Vij R; Schroeder MA
Leuk Lymphoma; 2021 Dec; 62(12):3043-3046. PubMed ID: 34142630
[TBL] [Abstract][Full Text] [Related]
38. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
39. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.
Zamagni E; Dhanasiri S; Ghale A; Moore A; Roussel M
Leuk Lymphoma; 2021 Oct; 62(10):2492-2501. PubMed ID: 34121589
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
